Glycopyrronium bromide/formoterol

From WikiMD's Wellness Encyclopedia

(Redirected from Bevespi Aerosphere)

Glycopyrronium bromide/formoterol is a combination medication used in the management of COPD. It contains two active ingredients: Glycopyrronium bromide and Formoterol.

Etymology[edit | edit source]

The name "Glycopyrronium bromide" is derived from its chemical structure, which includes a glycopyrrolate moiety and a bromide ion. The name "Formoterol" is derived from its chemical structure, which includes a formamide moiety and a phenol group.

Pharmacology[edit | edit source]

Glycopyrronium bromide is a Muscarinic antagonist, which works by blocking the action of acetylcholine on muscarinic receptors in the lungs, thereby reducing bronchoconstriction. Formoterol is a long-acting beta2-adrenoceptor agonist (LABA), which works by stimulating beta2-adrenoceptors in the lungs, thereby causing bronchodilation.

Clinical Use[edit | edit source]

Glycopyrronium bromide/formoterol is used as a maintenance treatment for COPD. It is not used for the relief of acute symptoms, i.e., as a rescue therapy. The medication is administered via inhalation.

Side Effects[edit | edit source]

Common side effects of glycopyrronium bromide/formoterol include dry mouth, nasopharyngitis, and upper respiratory tract infection. Less common side effects include urinary retention, blurred vision, and palpitations.

Related Terms[edit | edit source]

Glycopyrronium bromide/formoterol Resources

Contributors: Prab R. Tumpati, MD